ADRA1B encodes the alpha-1B adrenergic receptor, a G protein-coupled receptor that mediates catecholamine signaling through G(q) family proteins and the phosphatidylinositol-calcium pathway. The receptor binds norepinephrine and epinephrine to regulate vascular function, with genetic variants contributing to interindividual differences in adrenergic vasoconstriction responses 1. ADRA1B demonstrates tissue-specific regulatory roles, particularly in cardiac myocytes where nuclear ADRA1B forms heterooligomers with ADRA1A to regulate ERK signaling and interacts with CAVIN4/MURC at the plasma membrane to control cardiac hypertrophy. In dental pulp stem cells, ADRA1B mediates sympathetic nervous system effects by promoting metabolic reprogramming from oxidative phosphorylation to glycolysis, thereby inhibiting cell proliferation, migration, and odontoblast differentiation 23. The receptor shows clinical relevance across multiple contexts: variants associate with psoriasis susceptibility in Chinese populations 4, while alpha-1 antagonists targeting ADRA1B enhance neuroblastoma sensitivity to differentiation therapy, suggesting therapeutic potential 5. Additionally, ADRA1B variants show smoking-associated methylation interactions in human brain tissue, implicating the receptor in addiction neurobiology 6. These findings establish ADRA1B as a multifunctional receptor with roles in cardiovascular regulation, stem cell biology, and disease pathogenesis.